Clinical Significance Of Serum Autoantibodies In Idiopathic Interstitial Pneumonia

Kang, Byeong Seong; Park, Jin Kyeong; Roh, Jae‐Hyung; Song, Jin Woo; Lee, Chang Keun; Kim, Miyoung; Jang, Se Jin; Kim, Dong Soon

doi:10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6613

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detection of autoantibodies can assist in changing the diagnosis of IIP to CTD-ILD in up to 19% of cases in ILD clinics. [32][33][34][35] Guidelines from the American Thoracic Society and European Respiratory Society (ATS/ERS) recommend testing for antinuclear antibody (ANA), anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF) in all patients with suspected ILD. 36 Because the diagnosis of CTD-ILD has implications for treatment and prognosis, if there is any suggestion of CTD symptoms, a more detailed autoimmune screen can be performed (Table 3) and review by a rheumatologist or immunologist is advisable.…”

Section: Serology and Other Blood Testsmentioning

confidence: 99%

The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia

et al. 2017

View full text Add to dashboard Cite

Interstitial lung diseases (ILD) are a diverse group of pulmonary diseases for which accurate diagnosis is critical for optimal treatment outcomes. Diagnosis of ILD can be challenging and a multidisciplinary approach is recommended in international guidelines. The purpose of this position paper is to review the evidence for the use of the multidisciplinary meeting (MDM) in ILD and suggest an approach to its governance and constitution, in an attempt to provide a standard methodology that could be applied across Australia and New Zealand. This position paper is endorsed by the Thoracic Society of Australia and New Zealand (TSANZ) and the Lung Foundation Australia (LFA).

show abstract